HAART has increased the life expectancy of HIV-infected individuals significantly. Optimal adherence to HAART results in viral suppression and immune recovery in the majority of HIV-infected persons. Data from the early HAART era suggest that adherence levels of greater than 95% are necessary to achieve and maintain virological suppression. However, the optimal threshold of adherence required to maximize the pharmacological benefits of contemporary antiretroviral regimens, particularly in the virologically suppressed patient, is unknown. This review examines new data on the role of adherence in the late HAART era, focusing on virological, immunological and epidemiological aspects. We begin with a discussion of the impact of adherence on viral dynamics and immunological parameters in the virologically suppressed patient. We then review the importance of adherence in emerging antiretroviral treatment strategies. Finally, we summarize accumulating data on the role of antiretroviral adherence in the prevention of HIV transmission. Taken together, the data reviewed reinforce the critical importance of adherence in the management of HIV infection in the late HAART era.
References
1.
Antiretroviral Therapy Cohort Collaboration.Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet2008; 372: 293–299.
2.
PernoC.F., Ceccherini-SilbersteinF., De LucaA.Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr2002; 31Suppl 3: S118–S122.
3.
PatersonD.L., SwindellsS., MohrJ.Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med2000; 133: 21–30.
4.
ArnstenJ.H., DemasP.A., FarzadeganH.Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis2001; 33: 1417–1423.
5.
LedergerberB., CavassiniM., BattegayM.Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Med2011; 12: 279–288.
6.
RosenblumM., DeeksS.G., van der LaanM., BangsbergD.R.The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE2009; 4: e7196.
7.
LimaV.D., BangsbergD.R., HarriganP.R.Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr2010; 55: 460–465.
8.
ShuterJ.Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother2008; 61: 769–773.
9.
GulickR.M.Adherence to antiretroviral therapy: how much is enough?Clin Infect Dis2006; 43: 942–944.
10.
CohenC.J., ColsonA.E., Sheble-HallA.G., McLaughlinK.A., MorseG.D.Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials2007; 8: 19–23.
11.
ParientiJ.J., Das-DouglasM., MassariV.Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS ONE2008; 3: e2783.
12.
BraithwaiteR.S., KozalM.J., ChangC.C.Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS2007; 21: 1579–1589.
13.
ShuterJ., SarloJ.A., KanmazT.J., RodeR.A., ZingmanB.S.HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr2007; 45: 4–8.
14.
CohenM.S., GayC., KashubaA.D.M., BlowerS., PaxtonL.Antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med2007; 146: 591–601.
15.
EdénA., FuchsD., HagbergL.HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis2010; 202: 1819–1825.
16.
LetendreS., Marquie-BeckJ., CapparelliE.Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol2008; 65: 65–70.
17.
CanestriA., LescureF.X., JaureguiberryS.Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis2010; 50: 773–778.
18.
AntinoriA., GiancolaM.L., GrisettiS.Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS2002; 16: 1867–1876.
19.
EttenhoferM.L., FoleyJ., CastellonS.A., HinkinC.H.Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology2010; 74: 1217–1222.
20.
Cu-UvinS., DeLongA.K., VenkateshK.K.Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS2010; 24: 2489–2497.
21.
GrahamS.M., MaseseL., GitauR.Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis2010; 202: 1538–1542.
22.
ChoudhuryB., PillayD., TaylorS., CaneP.A.Analysis of HIV-1 variation in blood and semen during treatment and treatment interruption. J Med Virol2002; 68: 467–472.
23.
BarrosoP.F., SchechterM., GuptaP., BressanC., BomfimA., HarrisonL.H.Adherence to antiretroviral therapy and persistence of HIV RNA in semen. J Acquir Immune Defic Syndr2003; 32: 435–440.
24.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 14 October 2011. Accessed 15 April 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
25.
MinkoffH., ZhongY., BurkR.D.Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis2010; 201: 681–690.
26.
BernalA., WaltersS.T., PaulsonR.M., MubasherM.Effect of patient adherence to antiretroviral therapy on the progression of cervical dysplasia among HIV-infected women. AIDS Read2008; 18: 382–385.
27.
ParedesR., LalamaC.M., RibaudoH.J.Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis2010; 201: 662–671.
28.
RobbinsG.K., DanielsB., ZhengH., ChuehH., MeigsJ.B., FreedbergK.A.Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr2007; 44: 30–37.
29.
SizmannD., GlaubitzJ., SimonC.O.Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach. J Clin Virol2010; 49: 41–46.
30.
GerettiA.M., SmithC., HaberlA.Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther2008; 13: 927–936.
31.
MavignerM., DelobelP., CazabatM.HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS ONE2009; 4: e7658.
32.
HavlirD.V., KoelschK.K., StrainM.C.Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis2005; 191: 1164–1168.
33.
EggenaM.P., BarugahareB., JonesN.Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol2005; 174: 4407–4414.
34.
OstrowskiS.R., KatzensteinT.L., PedersenB.K., GerstoftJ., UllumH.Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers. Scand J Immunol2008; 68: 652–660.
35.
GandhiR.T., ZhengL., BoschR.J.The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med2010; 7: e1000321.
36.
HatanoH., HayesT.L., DahlV.A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis2011; 203: 960–968.
37.
TaiwoB., HicksC., EronJ.Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1. J Antimicrob Chemother2010; 65: 1100–1107.
38.
BiermanW.F., van AgtmaelM.A., NijhuisM., DannerS.A., BoucherC.A.HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS2009; 23: 279–291.
39.
ArribasJ.R., DelgadoR., ArranzA.Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr2009; 51: 147–152.
40.
PulidoF., Pérez-ValeroI., DelgadoR.Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther2009; 14: 195–201.
41.
KatlamaC., ValantinM.A., Algarte-GeninM.Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS2010; 24: 2365–2374.
42.
ArribasJ.R., HorbanbA., GerstoftcJ.The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS2010; 24: 223–230.
43.
VernazzaP., DaneelS., SchifferV.The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS2007; 21: 1309–1315.
44.
GutmannC., CusiniA., GünthardH.F.Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS2010; 24: 2347–2354.
45.
RiddlerS.A., HaubrichR., DiRienzoA.G.Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med2008; 358: 2095–2106.
46.
BabafemiT., SummerZ., SebastienG.Results from a single arm study of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).18th Conference on Retroviruses and Opportunistic Infections. 27 February – 2 March, 2011, Boston, MA, USA. Poster 551.
47.
CorderyD.V., HesseK., AminJ., CooperD.A.Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther2010; 15: 1035–1038.
48.
AiroldiM., ZaccarelliM., BisiL.One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV- infected subjects. Patient Prefer Adherence.2010; 4: 115–125.
49.
WeberJ., TatoudR., FidlerS.Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS2010; 24Suppl 4: S27–S39.
50.
Abdool KarimQ., Abdool KarimS.S., FrohlichJ.A., GroblerA.C., BaxterC., MansoorL.E.Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010; 329: 1168–1174.
51.
GrantR.M., LamaJ.R., AndersonP.L.Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med2010; 363: 2587–2599.
52.
BentzL., EnelP., DunaisB.Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial. AIDS Care2010; 22: 1509–1516.
53.
LundingS., KatzensteinT.L., KronborgG.The Danish PEP registry: experience with the use of postexposure prophylaxis (PEP) following sexual exposure to HIV from 1998 to 2006. Sex Transm Dis2010; 37: 49–52.
54.
LingappaJ.R., HughesJ.P., WangR.S.Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS ONE2010; 5: e12598.
55.
DonnellD., BaetenJ.M., KiarieJ.Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet2010; 375: 2092–2098.
56.
CohenM.S., ChenY.Q., McCauleyM.Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med2011; 365: 493–505.
57.
KalichmanS.C., CherryC., AmaralC.M.Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention. AIDS Patient Care STDS2010; 24: 271–277.
58.
GoldieS.J., FreedbergK.A., WeinsteinM.C., WrightT.C., KuntzK.M.Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med2001; 111: 140–149.
59.
MannheimerS.B., MorseE., MattsJ.P.Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr2006; 43Suppl 1: S41–S47.
60.
TrottaM.P., AmmassariA., MelziS.Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr2002; 31Suppl 3: S128–S131.
